v1
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma
NobleIDNI6P31W20R74S76
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260526/F98ACCE2)
ARK Inflections
Metadata Formats
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims